Use of Physiologically Based Pharmacokinetic (PBPK) Models to Quantify the Impact of Human Age and Interindividual Differences in Physiology and Biochemistry Pertinent to Risk (Final Report)
EPA announced the availability of the final report, Use of Physiologically Based Pharmacokinetic (PBPK) Models to Quantify the Impact of Human Age and Interindividual Differences in Physiology and Biochemistry Pertinent to Risk Final Report for Cooperative Agreement. This report describes and demonstrates techniques necessary to extrapolate and incorporate in vitro derived metabolic rate constants in PBPK models. It also includes two case study examples designed to demonstrate the applicability of such data for health risk assessment and addresses the quantification, extrapolation and interpretation of advanced biochemical information on human interindividual variability of chemical metabolism for risk assessment application. It comprises five chapters; topics and results covered in the first four chapters have been published in the peer reviewed scientific literature.
Topics covered include:
Topics covered include:
- Data Quality Objectives
- Experimental Framework
- Required Data
- Two example case studies that develop and incorporate in vitro metabolic rate constants in PBPK models designed to quantify human interindividual variability to better direct the choice of uncertainty factors for health risk assessment.
This report is the result of Cooperative Agreement CR828047010 between US EPA/ORD/NCEA and the Chemical Industry Institute for Toxicology(CIIT) and Dr Gregory Kedderis.
This is the final document. Results from Chapter 5 (the final case study) will be published in the peer reviewed literature.
U.S. EPA. Use of Physiologically Based Pharmacokinetic (PBPK) Models to Quantify the Impact of Human Age and Interindividual Differences in Physiology and Biochemistry Pertinent to Risk (Final Report). U.S. Environmental Protection Agency, Washington, D.C., EPA/600/R-06/014A.
|2002/03||Chapters 1-4 results were published in peer reviewed literature.|
|Jul 2004||A draft of Chapter 5 was released for internal review.|
|Oct 2004||A draft of Chapter 5 released for external review.|
|Dec 2004||Simplified acquisition developed to refine the final case study (Chapter 5).|
|Jun 2005||A draft of the full document was subjected to peer consultation.|
|Apr 2006||EPA released the final report.|
This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.
- (234 pp, 3 MB, about PDF)
- Application of in Vitro Biotransformation Data and Pharmacokinetic Modeling to Risk Assessment
- Incorporating Human Interindividual Biotransformation Variance in Health Risk Assessment
- Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (External Review Draft 2005)